Results 61 to 70 of about 510,312 (368)
JNCI Cancer Spectrum, 2019 Background Meta-analysis of randomized controlled trials (RCTs) has been widely conducted for the evaluation of surrogate endpoints in oncology, but little attention has been given to the adequacy of reporting and interpretation.
W. Xie +8 more
semanticscholar +1 more source
Applications of neuroimaging to disease-modification trials in Alzheimer's disease. [PDF]
, 2009 Critical to development of new therapies for Alzheimer's disease (AD) is the ability to detect clinical or pathological change over time. Clinical outcome measures typically used in therapeutic trials have unfortunately proven to be relatively variable ...
Aisen, Paul S +5 more
core +2 more sources
Journal of the American Society of Nephrology, 2019 BACKGROUND Randomized trials of CKD treatments traditionally use clinical events late in CKD progression as end points. This requires costly studies with large sample sizes and long follow-up.
T. Greene +14 more
semanticscholar +1 more source
Evaluating Candidate Principal Surrogate Endpoints
Biometrics, 2008 Summary Frangakis and Rubin (2002, Biometrics 58, 21–29) proposed a new definition of a surrogate endpoint (a “principal” surrogate) based on causal effects. We introduce an estimand for evaluating a principal surrogate, the causal effect predictiveness (CEP) surface, which quantifies how well causal treatment effects on the biomarker predict causal ...
Gilbert, Peter B., Hudgens, Michael G.
openaire +3 more sources
Evidence regarding clinical use of microvolt T-wave alternans [Accuracy of microvolt T-wave alternans testing] [PDF]
, 2011 Background: Microvolt T-wave alternans (MTWA) testing in many studies has proven to be a highly accurate predictor of ventricular tachyarrhythmic events (VTEs) in patients with risk factors for sudden cardiac death (SCD) but without a prior history of ...
Cohen, Richard J. +2 more
core
Pathogenic Germline PALB2 and RAD50 Variants in Patients With Relapsed Ewing Sarcoma
Pediatric Blood &Cancer, EarlyView.ABSTRACT Approximately 10% of patients with Ewing sarcoma (EwS) have pathogenic germline variants. Here, we report two cases: first, a novel germline pathogenic variant in partner and localizer of BRCA2 (PALB2) in a patient with a late EwS relapse. Its impact on homologous recombination is demonstrated, and breast cancer risk is discussed.
Molly Mack +12 more
wiley +1 more source
What can we learn from SOCRATES: more questions than answers? [PDF]
, 2017 This editorial refers to ‘Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) Study’, by B ...
Cleland, John G.F., Mueller, Christian
core +1 more source
A modified weighted log-rank test for confirmatory trials with a high proportion of treatment switching [PDF]
, 2020 In confirmatory cancer clinical trials, overall survival (OS) is normally a primary endpoint in the intention-to-treat (ITT) analysis under regulatory standards. After the tumor progresses, it is common that patients allocated to the control group switch
Bore, Alexander +3 more
core +2 more sources
BMJ Open, 2022 Introduction Randomised controlled trials (RCTs) may use surrogate endpoints as substitutes and predictors of patient-relevant/participant-relevant final outcomes (eg, survival, health-related quality of life).
Martin Offringa +10 more
doaj +1 more source
Comparing Biomarkers as Principal Surrogate Endpoints [PDF]
Biometrics, 2011 Recently a new definition of surrogate endpoint, the "principal surrogate," was proposed based on causal associations between treatment effects on the biomarker and on the clinical endpoint. Despite its appealing interpretation, limited research has been conducted to evaluate principal surrogates, and existing methods focus on risk models that consider
Huang, Ying, Gilbert, Peter B.
openaire +3 more sources